ProCE Banner Activity

Expert Answers to FAQs on HER2-, HER3-, and TROP-2–Directed ADCs for Pharmacists

Clinical Thought

Focused commentary answering healthcare professionals’ questions on HER2, HER3, and TROP-2–directed ADCs for pharmacists, including recommendations on management of interstitial lung disease, shortening infusion times, and dose rounding.

Released: April 23, 2024

Expiration: April 22, 2025

Share

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Allison Butts, PharmD, BCOP

Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
UK HealthCare
Markey Cancer Center
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has no relevant financial relationships to disclose.

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Associate Professor
University of Illinois College of Pharmacy
Oncology Clinical Pharmacist
UI Health
Chicago, Illinois

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP: consultant/advisor/speaker: Astellas.